within Pharmacolibrary.Drugs.ATC.B;

model B01AC13
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 0.25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 8.999999999999999e-05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0026,
    k12             = 0.18,
    k21             = 0.18
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AC13</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Abciximab is a chimeric human-murine monoclonal antibody fragment (Fab) that binds to the glycoprotein IIb/IIIa receptor on human platelets, inhibiting platelet aggregation. It is used as an adjunct to percutaneous coronary intervention (PCI) to prevent cardiac ischemic complications. It is an approved drug for use in adults undergoing PCI or those at high risk of acute cardiac events.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults undergoing percutaneous coronary intervention after single intravenous bolus followed by infusion.</p><h4>References</h4><ol><li><p>Zimarino, M, et al., &amp; De Caterina, R (2015). Intracoronary vs intravenous abciximab in interventional cardiology: A reopened question?. <i>Vascular pharmacology</i> 73 8–10. DOI:<a href=&quot;https://doi.org/10.1016/j.vph.2015.08.001&quot;>10.1016/j.vph.2015.08.001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26254107/&quot;>https://pubmed.ncbi.nlm.nih.gov/26254107</a></p></li><li><p>Ostrowska, M, et al., &amp; Kubica, J (2014). Off-target effects of glycoprotein IIb/IIIa receptor inhibitors. <i>Cardiology journal</i> 21(5) 458–464. DOI:<a href=&quot;https://doi.org/10.5603/CJ.a2014.0020&quot;>10.5603/CJ.a2014.0020</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24526503/&quot;>https://pubmed.ncbi.nlm.nih.gov/24526503</a></p></li><li><p>Van Tuyl, JS, et al., &amp; Hollis, IB (2019). Perioperative Bridging With Glycoprotein IIb/IIIa Inhibitors Versus Cangrelor: Balancing Efficacy and Safety. <i>The Annals of pharmacotherapy</i> 53(7) 726–737. DOI:<a href=&quot;https://doi.org/10.1177/1060028018824640&quot;>10.1177/1060028018824640</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30646761/&quot;>https://pubmed.ncbi.nlm.nih.gov/30646761</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AC13;
